KS

Kevin Slawin

Founder and CEO, Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc., both located in Houston, TX, that are using advanced technologies in novel ways to develop the first therapeutics to arrest or reverse aging.

Miami Beach, Florida

Invests in

Stages:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $10,000,000.00
  • Target Investment:

    $100,000.00

Work Experience

  • Chairman and CEO

    2023

    “Powered by Advanced and Clinically Tested Bioprinting Technologies” Our lead product is 3DMatrix™, a 3D-printed monofilament bioresorbable surgical mesh has received FDA 510(k) clearance.

  • Founder, CEO and Chairman

    2021

    Applying high throughput DNA encoded library (DEL) drug screening technologies in novel ways to deliver therapeutics that address the most difficult problems in clinical medicine

  • Founder CEO and Chairman

    2019

    Using advanced, proprietary technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs utilize proprietary, state-of-the-art biotechnology platforms to restore the youthful balance of aged or “senescent” and young cells in the skin, targeting the senescent cells for elimination. This provides a “reboot” of one’s genetic program to turn the clock on one’s skin back to its youthful exuberance.

  • Founder and Managing Partner

    2018

    Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

  • Chairman of the Board

    2022

    Conquering the Last Frontier in Patient Monitoring. FIZE® Medical offers the first platform technology to remotely monitor and manage patients with an indwelling Foley catheter, providing unprecedented safety to both patients and their caregivers.

  • Board Member

    2020 - 2022

  • Founder and Chairman

    2021

    Physicians, founders, executives and investors working to expand the entrepreneurial healthcare ecosystem in Miami

  • Chairman of the Board

    2021

    Building a Best-in-class Urologic Oncology Company. Developing technologies to better visualize and treat urologic cancers through minimally invasive procedures in the physicians’ office

2021

  • Founding Board Member

    2021

    Enabling promising early-stage life science companies to develop the next generation of innovative therapies to improve the lives of patients. We want to do this by offering them Contract Research Organization (CRO) Services, newly renovated wet-lab space, process and analytical development support, short-term financing, and third-party due diligence validation, among other services.

  • Board Member

    2020

  • Co-Founder, Managing Member and CMO

    2020